Dtsch Med Wochenschr 2013; 138(15): 792-798
DOI: 10.1055/s-0032-1332997
Übersicht | Review article
Gastroenterologie, Onkologie
© Georg Thieme Verlag KG Stuttgart · New York

Therapie von Lebermetastasen des kolorektalen Karzinoms: Übersicht der hyperthermen Ablationsverfahren

Treatment of liver metastases of colorectal carcinoma: Overview of hyperthermal ablation methods
T. J. Vogl
1   Institut für Diagnostische und Interventionelle Radiologie, JWG Universitätsklinikum Frankfurt
,
A. Zegelman
1   Institut für Diagnostische und Interventionelle Radiologie, JWG Universitätsklinikum Frankfurt
,
W. O. Bechstein
2   Klinik für Allgemein- und Viszeralchirurgie, JWG Universitätsklinikum Frankfurt
,
S. Zeuzem
3   Zentrum für Innere Medizin, Medizinische Klinik I, JWG Universitätsklinikum Frankfurt
,
S. Zangos
1   Institut für Diagnostische und Interventionelle Radiologie, JWG Universitätsklinikum Frankfurt
› Author Affiliations
Further Information

Publication History

08 October 2012

10 January 2013

Publication Date:
02 April 2013 (online)

Zusammenfassung

Zielsetzung und Methode: In dieser Arbeit werden die technischen Grundlagen und klinischen Ergebnisse gebräuchlicher hyperthermer Ablationsverfahren zur Therapie von Lebermetastasen des kolorektalen Karzinoms dargestellt. Mit einer selektiven Literaturrecherche in gängigen Datenbanken und anhand eigener klinischer Erfahrung an einem interdisziplinären Leberzentrum eines Universitätsklinikums wurden bereits publizierte Daten zusammengestellt und vergleichend bewertet.

Ergebnis: Für Radiofrequenzablation (RFA), Mikrowellenablation (MWA) und Laserablation (LITT) ergaben sich vergleichbare Überlebensdaten. Lokalrezidive waren nach LITT (Mittel: 7,1–10 %) etwas seltener zu beobachten als nach RFA (Mittel: 32–44 %) und MWA (Mittel: 7–15 %). Die Überlebensdaten hängen von vielen Faktoren ab. Die 3-Jahres-Überlebensraten liegen für die RFA zwischen 20,2–71,3 %, für die MWA bei 51,1 % und für die LITT zwischen 56–77 %. Die Komplikationen liegen im Mittel bei 1,8–10 %. Aktuelle Studien, welche die Thermoablationsverfahren mit lokal applizierter Chemo- oder Radiotherapie kombinieren, zeigen vielversprechende Ergebnisse.

Schlussfolgerung: RFA, MWA und LITT bieten eine gute lokale Tumorkontrolle bei ambulanter Durchführbarkeit und geringer Komplikationsrate. Indiziert sind diese Verfahren bei auf die Leber beschränkter Metastasierung mit < 5 Metastasen und einem maximalen Durchmesser ≤ 4 cm, wenn Leberresektion kontraindiziert oder bereits erfolgt ist. Die Indikation wird durch ein interdisziplinäres Tumorboard getroffen.

Abstract

Aim and method: This paper presents the basic techniques and clinical results of the most common hyperthermal ablation methods for patients with malignant liver metastases of colorectal carcinoma. An overview of recently published data is provided using selected articles from the literature and our own clinical experience in an interdisciplinary liver centre.

Results: Radiofrequency ablation (RFA), microwave ablation (MWA) and laser ablation (LITT) show comparable results concerning survival data. Local recurrence is less frequent after LITT (7,1–10 %) than after RFA (32–44 %) and MWA (7–15 %). Survival depends on many factors. The 3-year survival rate for RFA ranges from 20,2–71,3 %, for MWA it is 51,1 % and for LITT from 56–77 %. Mean complication rates range from 1,8–10 %. Recent studies showed promising results after combined therapy of regional chemotherapy or regional radiotherapy with thermal ablation.

Conclusion: Ablation methods such as RFA, MWA and LITT show good local tumor control with low complication rates and are usually performed on an outpatient basis. Indications are < 5 metastases limited to the liver with a maximum diameter of ≤ 4 cm when surgical resection is contraindicated or has been previously performed. The decision should be made by an interdisciplinary tumor board.

 
  • Literatur

  • 1 Abdalla EK, Vauthey JN, Ellis LM et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004; 239: 818-825; discussion 825-827
  • 2 Aikata H, Shirakawa H, Takaki S et al. Radiofrequency ablation combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma. Hepatology 2006; 44: 494A
  • 3 Akyildiz HY, Mitchell J, Milas M et al. Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: long-term follow-up. Surgery 2010; 148: 1288-1293; discussion 1293
  • 4 Bangard C. [Radiofrequency of the liver – an update]. Rofo 2011; 183: 704-713
  • 5 Berber E, Flesher N, Siperstein AE. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J Surg 2002; 26: 985-990
  • 6 Bloomston M, Binitie O, Fraiji E et al. Transcatheter arterial chemoembolization with or without radiofrequency ablation in the management of patients with advanced hepatic malignancy. Am Surg 2002; 68: 827-831
  • 7 Chen MS, Li JQ, Zheng Y et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006; 243: 321-328
  • 8 Curley SA, Marra P, Beaty K et al. Early and late complications after radiofrequency ablation of malignant liver tumors in 608 patients. Ann Surg 2004; 239: 450-458
  • 9 de Baere T, Risse O, Kuoch V et al. Adverse events during radiofrequency treatment of 582 hepatic tumors. AJR Am J Roentgenol 2003; 181: 695-700
  • 10 Eickmeyer F, Schwarzmaier HJ, Müller FP et al. [Survival after laser-induced interstitial thermotherapy of colorectal liver metastases – a comparison of first clinical experiences with current therapy results]. Rofo 2008; 180: 35-41
  • 11 Fong Y, Fortner J, Sun RL et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230: 309-318; discussion 318-321
  • 12 Gillams AR, Lees WR. Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation. Eur Radiol 2009; 19: 1206-1213
  • 13 Golling M, Bechstein W. Surgical resection of colorectal liver metastases – the current standard therapy (review). Rozhl Chir 2006; 85: 381-389
  • 14 Hoffmann RT, Jakobs TF, Kubisch CJ et al. Radiofrequency ablation after selective internal radiation therapy with Yttrium90 microspheres in metastatic liver disease – is it feasible?. Eur J Radiol 2010; 74: 199-205
  • 15 Katz AW, Carey-Sampson M, Muhs AG et al. Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases. Int J Radiat Oncol Biol Phys 2007; 67: 793-798
  • 16 Kong WT, Zhang WW, Qiu YD et al. Major complications after radiofrequency ablation for liver tumors: analysis of 255 patients. World J Gastroenterol 2009; 15: 2651-2656
  • 17 Lencioni R, Crocetti L, Cioni D et al. Percutaneous radiofrequency ablation of hepatic colorectal metastases: technique, indications, results, and new promises. Invest Radiol 2004; 39: 689-697
  • 18 Liang P, Dong BW, Yu XL et al. [Evaluation of long-term therapeutic effects of ultrasound-guided percutaneous microwave ablation of liver metastases]. Zhonghua Yi Xue Za Zhi 2006; 86: 806-810
  • 19 Liang P, Wang Y, Yu X et al. Malignant liver tumors: treatment with percutaneous microwave ablation – complications among cohort of 1136 patients. Radiology 2009; 251: 933-940
  • 20 Livraghi T, Solbiati L, Meloni MF et al. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology 2003; 226: 441-451
  • 21 Lu MD, Kuang M, Liang LJ et al. [Surgical resection versus percutaneous thermal ablation for early-stage hepatocellular carcinoma: a randomized clinical trial]. Zhonghua Yi Xue Za Zhi 2006; 86: 801-805
  • 22 Machi J, Oishi AJ, Sumida K et al. Long-term outcome of radiofrequency ablation for unresectable liver metastases from colorectal cancer: evaluation of prognostic factors and effectiveness in first- and second-line management. Cancer J 2006; 12: 318-326
  • 23 Martin RC, Scoggins CR, McMasters KM. Safety and efficacy of microwave ablation of hepatic tumors: a prospective review of a 5-year experience. Ann Surg Oncol 2010; 17: 171-178
  • 24 Mazzaglia PJ, Berber E, Milas M et al. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery 2007; 142: 10-19
  • 25 Mulier S, Mulier P, Ni Y et al. Complications of radiofrequency coagulation of liver tumours. Br J Surg 2002; 89: 1206-1222
  • 26 NICE. Radiofrequency ablation for the treatment of colorectal metastases in the liver. National Institute for Clinical Excellence (NICE); http://guidance.nice.org.uk/index.jsp?action=article&o=44990
  • 27 Otto G, Duber C, Hoppe-Lotichius M et al. Radiofrequency ablation as first-line treatment in patients with early colorectal liver metastases amenable to surgery. Ann Surg 2010; 251: 796-803
  • 28 Pech M, Wieners G, Freund T et al. MR-guided interstitial laser thermotherapy of colorectal liver metastases: efficiency, safety and patient survival. Eur J Med Res 2007; 12: 161-168
  • 29 Pereira PL, Clasen S, Hoffmann RT et al. Long-term survival after CT and MR-guided percutaneous radiofrequency ablation of colorectal metastases: clinical results of the German Study Group in Radiology Society of North America. 92nd Scientific Assembly. Chicago: 2006
  • 30 Rosenberg C, Puls R, Hegenscheid K et al. Laser ablation of metastatic lesions of the lung: long-term outcome. AJR Am J Roentgenol 2009; 192: 785-792
  • 31 Ruers T, Punt CJ, van Coevorden F et al. Final results of the EORTC intergroup randomized study 40004 (CLOCC) evaluating the benefit of radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM). Abstract No 3526. J Clin Oncol 2010; 28 (Suppl. 01) 15s
  • 32 Rusthoven KE, Kavanagh BD, Cardenes H et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 2009; 27: 1572-1578
  • 33 Shibata T, Isoda H, Hirokawa Y et al. Small hepatocellular carcinoma: is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment?. Radiology 2009; 252: 905-913
  • 34 Shibata T, Niinobu T, Ogata N et al. Microwave coagulation therapy for multiple hepatic metastases from colorectal carcinoma. Cancer 2000; 89: 276-284
  • 35 Siperstein AE, Berber E, Ballem N et al. Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience. Ann Surg 2007; 246: 559-565; discussion 565-567
  • 36 Solbiati L, Ierace T, Tonolini M et al. Radiofrequency thermal ablation of hepatic metastases. Eur J Ultrasound 2001; 13: 149-158
  • 37 Solbiati L, Livraghi T, Goldberg SN et al. Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology 2001; 221: 159-165
  • 38 Sørensen SM, Mortensen FV, Nielsen DT. Radiofrequency ablation of colorectal liver metastases: long-term survival. Acta Radiol 2007; 48: 253-258
  • 39 Vogl TJ, Naguib NN, Nour-Eldin NE et al. Unresectable liver metastases of colorectal carcinoma: repeated transarterial chemoembolisation using different chemotherapeutic drug combinations followed by MR-guided laser-induced thermotherapy. Vienna: European Congress of Radiology; 2011
  • 40 Vogl TJ, Mack MG, Balzer JO et al. Liver metastases: neoadjuvant downsizing with transarterial chemoembolization before laser-induced thermotherapy. Radiology 2003; 229: 457-464
  • 41 Vogl TJ, Straub R, Eichler K et al. Colorectal carcinoma metastases in liver: laser-induced interstitial thermotherapy – local tumor control rate and survival data. Radiology 2004; 230: 450-458
  • 42 Vogl TJ, Straub R, Eichler K et al. Malignant liver tumors treated with MR imaging-guided laser-induced thermotherapy: experience with complications in 899 patients (2,520 lesions). Radiology 2002; 225: 367-377